These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18593009)

  • 41. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The search for a cure for Duchenne muscular dystrophy (DMD).
    Acta Myol; 2005 Dec; 24(3):169-71. PubMed ID: 16629049
    [No Abstract]   [Full Text] [Related]  

  • 43. Special Issue "Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy".
    Arechavala-Gomeza V; Gonzalez-Quereda L
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33567614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duchenne muscular dystrophy: issues in expanding newborn screening.
    Kemper AR; Wake MA
    Curr Opin Pediatr; 2007 Dec; 19(6):700-4. PubMed ID: 18025940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
    Gatheridge MA; Kwon JM; Mendell JM; Scheuerbrandt G; Moat SJ; Eyskens F; Rockman-Greenberg C; Drousiotou A; Griggs RC
    JAMA Neurol; 2016 Jan; 73(1):111-6. PubMed ID: 26594870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy.
    Cripe LH; Tobias JD
    Paediatr Anaesth; 2013 Sep; 23(9):777-84. PubMed ID: 23869433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next Generation Sequencing approach to molecular diagnosis of Duchenne muscular dystrophy; identification of a novel mutation.
    Ebrahimzadeh-Vesal R; Teymoori A; Azimi-Nezhad M; Hosseini FS
    Gene; 2018 Feb; 644():1-3. PubMed ID: 29246534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Introduction to the Duchenne Muscular Dystrophy Care Considerations.
    Ward LM; Birnkrant DJ
    Pediatrics; 2018 Oct; 142(Suppl 2):S1-S4. PubMed ID: 30275244
    [No Abstract]   [Full Text] [Related]  

  • 49. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004.
    Biggar WD; Bachrach LK; Henderson RC; Kalkwarf H; Plotkin H; Wong BL
    Neuromuscul Disord; 2005 Jan; 15(1):80-5. PubMed ID: 15639125
    [No Abstract]   [Full Text] [Related]  

  • 50. Transition in Duchenne muscular dystrophy: An expert meeting report and description of transition needs in an emergent patient population: (Parent Project Muscular Dystrophy Transition Expert Meeting 17-18 June 2011, Amsterdam, The Netherlands).
    Schrans DG; Abbott D; Peay HL; Pangalila RF; Vroom E; Goemans N; Vles JS; Aldenkamp AP; Hendriksen JG;
    Neuromuscul Disord; 2013 Mar; 23(3):283-6. PubMed ID: 22989602
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of three genetic musculoskeletal diseases: a comparative synthesis of achondroplasia, Duchenne muscular dystrophy and osteogenesis imperfecta.
    Dogba MJ; Rauch F; Douglas E; Bedos C
    Health Qual Life Outcomes; 2014 Oct; 12():151. PubMed ID: 25649344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duchenne muscular dystrophy in the Western Cape, South Africa: Where do we come from and where are we going?
    Esterhuizen AI; Greenberg LJ; Ballo R; Goliath RG; Wilmshurst JM
    S Afr Med J; 2016 May; 106(6 Suppl 1):S67-71. PubMed ID: 27245531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From the smallest virus to the biggest gene: marching towards gene therapy for duchenne muscular dystrophy.
    Duan D
    Discov Med; 2006 Jun; 6(33):103-8. PubMed ID: 17234143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
    Wilson K; Faelan C; Patterson-Kane JC; Rudmann DG; Moore SA; Frank D; Charleston J; Tinsley J; Young GD; Milici AJ
    Toxicol Pathol; 2017 Oct; 45(7):961-976. PubMed ID: 28974147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perspectives of stem cell therapy in Duchenne muscular dystrophy.
    Meregalli M; Farini A; Belicchi M; Parolini D; Cassinelli L; Razini P; Sitzia C; Torrente Y
    FEBS J; 2013 Sep; 280(17):4251-62. PubMed ID: 23206279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Skipping to new gene therapies for muscular dystrophy.
    Tidball JG; Spencer MJ
    Nat Med; 2003 Aug; 9(8):997-8. PubMed ID: 12894160
    [No Abstract]   [Full Text] [Related]  

  • 58. Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy.
    Banihani R; Smile S; Yoon G; Dupuis A; Mosleh M; Snider A; McAdam L
    J Child Neurol; 2015 Oct; 30(11):1472-82. PubMed ID: 25660133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duchenne muscular dystrophy: Still an incurable disease.
    Arora H
    Neurol India; 2019; 67(3):717-723. PubMed ID: 31347542
    [No Abstract]   [Full Text] [Related]  

  • 60. Duchenne muscular dystrophy: genome editing gives new hope for treatment.
    Crispi V; Matsakas A
    Postgrad Med J; 2018 May; 94(1111):296-304. PubMed ID: 29386334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.